Trial · NCT00105066
The Effects of Metformin on Blood Vessel Structure and Function
NCT00105066, Phase 2, Completed, National Institute on Aging (NIA); results first posted 2017-01-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Effects of Metformin on Blood Vessel Structure and Function. Trials, record NCT00105066. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00105066
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects of Metformin on Blood Vessel Structure and Function
- NCT number
- NCT00105066
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 77 participants, actual
- Lead sponsor
- National Institute on Aging (NIA)
- Conditions
- Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
- Interventions
- Metformin, Placebo
- First posted
- 2005-03-04
- Last updated
- 2017-01-18
- Results first posted
- 2017-01-18
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Arterial Stiffness Compared to Baseline | Baseline and 4.5 months | |
| Primary | Change in Flow Mediated Dilation (FMD) | Baseline and 4.5 months | to evaluate improvement in endothelial function |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Arterial Stiffness Compared to Baseline | Baseline and 4.5 months | meters / second | MEAN | |
| PRIMARY | Change in Flow Mediated Dilation (FMD) | Baseline and 4.5 months | Participants with complete data. | percentage change in diameter | MEAN |
| POST_HOC | Homa Insulin Sensitivity | 4.5 months | Participants with complete data. | HOMA Score | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Arterial Stiffness Compared to Baseline | Placebo | -7.2 | Standard Deviation 2.1 | meters / second | |
| Change in Arterial Stiffness Compared to Baseline | Metformin | -7.3 | Standard Deviation 1.8 | meters / second | |
| Change in Flow Mediated Dilation (FMD) | Placebo | 8.8 | Standard Deviation 7.0 | percentage change in diameter | |
| Change in Flow Mediated Dilation (FMD) | Metformin | 10.5 | Standard Deviation 8.0 | percentage change in diameter | |
| Homa Insulin Sensitivity | Placebo | 57.4 | Standard Deviation 36.3 | HOMA Score | |
| Homa Insulin Sensitivity | Metformin | 64.5 | Standard Deviation 27.7 | HOMA Score |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 27 | |
| Overall Study | STARTED | Metformin | 50 | |
| Overall Study | COMPLETED | Placebo | 25 | |
| Overall Study | COMPLETED | Metformin | 45 | |
| Overall Study | NOT COMPLETED | Placebo | 2 | |
| Overall Study | NOT COMPLETED | Metformin | 5 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Placebo | 1 | 27 | 1 |
| other | Nausea | Gastrointestinal disorders | Metformin | 6 | 50 | 6 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Metformin | ||
| Total, other adverse events | Placebo | 1 | 27 |
| Total, other adverse events | Metformin | 6 | 50 |
| Total, serious adverse events | Placebo | 0 | 27 |
| Total, serious adverse events | Metformin | 0 | 50 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Metformin vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00105066
GET https://conductscience.org/api/trials/v1/NCT00105066/registered